Cagrilintide/semaglutide

< Cagrilintide
Cagrilintide/semaglutide
Combination of
CagrilintideAmylin receptor agonist
SemaglutideGLP-1 receptor agonist
Clinical data
Trade namesCagriSema

Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It has been proposed as a follow-on to Ozempic, Mounjaro, and Wegovy in obesity and Type II diabetes treatment.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.